Becton Dickinson and Co vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Becton Dickinson and Co trades at $182.45 (market cap $49.41B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $60.44. The key difference: Becton Dickinson and Co pays a 2.32% dividend while Vanguard Emerging Markets Stock Index Fund ETF pays none. Which is the better fit depends on your goals.
| BDX | VWO | |
|---|---|---|
Market Cap | $49.41B | — |
Sector | Health | — |
52-Week High | $185.39 | $61.24 |
52-Week Low | $138.62 | $51.20 |
Enterprise Value | $65.51B | — |
Dividend Yield | 2.32% | — |
Signals from Pluang's Aura AI — not financial advice
BDX trades at $180.64, up 0.56% today, near its consensus price target of $183. The stock shows bullish technical signals with strong moving averages and recent earnings beats in Q2 2026. Revenue growth is steady, with Q3 2026 reaching $5 billion, though margins face pressure from tariffs. The company maintains a Dividend Aristocrat status with consistent payouts.
Outlook is cautiously optimistic with analyst consensus leaning buy, but risks include margin compression and debt levels. The stock offers stability through dividends and sector resilience, yet investors should monitor earnings sustainability and competitive threats in the medical technology space.
VWO trades at $60.42, up 0.15% today, with a bullish technical signal driven by moving averages. The ETF shows strong institutional accumulation, with Barry Investment Advisors increasing holdings by 6.1% (SEC filing, August 10, 2026). RSI levels indicate mild overbought conditions, while support sits near $60.
Outlook remains positive due to record capital inflows into emerging markets and low 0.06% expense ratio. Risks include concentrated exposure to developing economies and China's economic volatility. The dividend yield of 2.4% offers income appeal amid global diversification trends.
Trailing returns across standard periods
Latest headlines on both assets
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →